4.7 Article

25-Hydroxycholesterol mitigates hepatic ischemia reperfusion injury via mediating mitophagy

期刊

INTERNATIONAL IMMUNOPHARMACOLOGY
卷 96, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.intimp.2021.107643

关键词

Hepatic I; R injury; 25-Hydroxycholesterol; Mitophagy; NLRP3 inflammasome

资金

  1. Medical Science Advancement Program (Clinical Medicine) of Wuhan University [TFLC2018003]
  2. Joint Foundation for Translational Medicine and Interdisciplinary Research in Zhongnan Hospital [ZNLH201903]

向作者/读者索取更多资源

The administration of 25-hydroxycholesterol (25HC) before ischemia has been shown to effectively mitigate liver ischemia reperfusion injury in rats, potentially by activating mitophagy and inhibiting NLRP3 inflammasome activation.
Hepatic ischemia reperfusion (I/R) injury remains a major obstacle in liver transplantation, however an effective treatment to mitigate this injury is lacking. 25-Hydroxycholesterol (25HC) is a kind of oxysterol involved in inflammatory and immune responses. However, its function and the underlying mechanism on rat hepatic I/R injury has not been explored. A well-established rat model of partial warm ischemia reperfusion injury was performed. 25HC was intraperitoneally administrated 4 h before ischemia. The results verified that 25HC pretreatment effectively mitigated liver I/R injury, which was demonstrated by lower serum levels of transaminases, histology injury score and less apoptosis. Mechanistically, 25HC pretreatment activated PINK1/Parkin dependent mitophagy and inhibited the NLRP3 inflammasome. Via using mitophagy inhibitor 3-methyladenine (3-MA), we further found that 3-MA counteracted the protective effect of 25HC on hepatic I/R injury and the NLRP3 inflammasome. In conclusion, 25HC pretreatment ameliorates rat hepatic I/R injury, and this protective effect may be dependent on activating mitophagy and inhibiting NLRP3 inflammasome activation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据